HuMax-AXL-ADC

HuMax®-AXL-ADC is an ADC targeted to AXL, a signaling molecule expressed on many solid cancers and implicated in tumor biology. HuMax-AXL-ADC is in Phase I/II development for five different types of solid tumors. HuMax-AXL-ADC is fully owned by Genmab and the ADC technology used with HuMax-AXL-ADC was licensed from Seattle Genetics

Back to top

HuMax-AXL-ADC  is being tested in five solid tumors (ovary, cervix, endometrium, lung and thyroid). For more information on these studies, visit clinicaltrials.gov

Back to top